Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 2019

View Archived Issues

Identification of variants in CTSD and ACP2 genes that could be protective against Parkinson's

Mutations in CFTR associated with development of COPD

Novel minigastrin analogue for PET imaging of CCK2R-expressing tumors

[68Ga]Ga-ProBOMB2 is a promising new GRPR-imaging PET radiotracer

Roche patents new antibacterials

Improved PSMA-targeting radiotherapeutic agents developed for prostate cancer

Phenex Discovery Verwaltungs discloses IDO1 inhibitors

Bayer synthesizes new AMPK inhibitors

Istituto Oncologico di Ricerca describes new compounds for cancer

Chinese investigators present UFO inhibitors

"Itchy" gut leads to pain sensitivity in IBS

Why smokers are prone to diabetes

AP2A2 gene tied to hereditary spastic paraplegia

University Hospital Heidelberg describes clinical testing of 18F-labeled FAPI tracer

IMbrave150 study of Tecentriq with Avastin in HCC meets coprimary endpoints

Phase II study of CV-301 in bladder cancer does not meet efficacy threshold to progress

Xuzhou Medical University describes CAR-T therapy targeting HBVsAg

Ultomiris approved in U.S. for atypical hemolytic uremic syndrome

FDA approves Farxiga to reduce risk of hospitalization for heart failure in type 2 diabetes patients

FDA grants approval to Amzeeq topical foam for acne

Primary endpoint met in HER2CLIMB trial of tucatinib in HER2-positive breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...